April 3, 2025

Model characterization and tumor immune profile assessment of syngeneic Renca murine renal cell carcinoma in female BALB/c. Snider J et al. AACR2025

Model growth kinetics and response to multiple treatment types were evaluated for syngeneic Renca murine renal cell carcinoma. Immune profile characterization was performed via flow cytometry to assess changes within the immune cell subsets following different treatment types and from control tumors at different tumor volumes.

April 3, 2025

Increasing translatability of syngeneic mouse models of cancer through the application of human-validated, clinically relevant gene expression-based measurements of the tumor immune microenvironment. Wallen ZD & Strickland KC et al. AACR2025

Analysis of syngeneic mouse models using human-validated immune gene expression (iGEX) measurements to assess tumor immune microenvironments and treatment responses demonstrated that in vivo tumor fragments exhibited higher immune activity than in vitro tumor cell lines and closely resembled iGEX measures in human tumors.

April 3, 2025

High TLR3 transcript levels correlate with high TIM3 and VISTA checkpoints but not with outcome after immune checkpoint blockade. Hsieh M et al. AACR2025

Evaluation of TLR3 RNA expression landscape in 514 real-world tumors with categorization into "High" or "Non-High" levels and analysis of associations with patient characteristics, immune markers and cancer subtypes, demonstrated a significant correlation between high TLR3 expression and other immune modulation targets such as VISTA and TIM3 RNA express